RxDoctor Payments Data

Christopher Baltes, MD

Family Medicine · Fort Wayne, INNPI 1992090971

Payments from drug & device makers

$1,203in general payments, 2019–2025

Across 76 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$268
  • Pfizer$126
  • AstraZeneca$124
  • Lilly USA, LLC$114
  • AbbVie$107
  • GSK$70
  • plus $394 from 13 others

What the payments were for

  • Food & beverage$1,18899%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,203 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$109,890
Medicare patients
308
Services billed
1,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban436$164,847
JardianceEmpagliflozin129$108,041
Soliqua 100-33Insulin Glargine/Lixisenatide56$56,367
JanuviaSitagliptin Phosphate108$48,441
XareltoRivaroxaban131$43,055
FarxigaDapagliflozin Propanediol78$40,208
GemtesaVibegron155$36,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$35,384
OzempicSemaglutide26$28,296
MyrbetriqMirabegron94$22,058
MounjaroTirzepatide20$21,356
TrulicityDulaglutide43$19,231
TradjentaLinagliptin54$16,614
NamzaricMemantine Hcl/Donepezil Hcl87$13,136
LinzessLinaclotide12$11,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$164,847436 claims
Boehringer IngelheimJardiance, Tradjenta$46$124,654183 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$34$59,99798 claims
MerckJanuvia, Janumet Xr$11$59,562119 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$124$55,237110 claims
Johnson & JohnsonXarelto$59$43,055131 claims
GSKTrelegy Ellipta, Anoro Ellipta$70$41,21944 claims
Lilly USA, LLCMounjaro, Trulicity$114$40,58763 claims
Novo NordiskOzempic$268$28,29626 claims
AbbVieNamzaric, Linzess$107$24,91899 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →